Related references
Note: Only part of the references are listed.A phase I open-label study to evaluate the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin (Dox) in patients with advanced soft tissue sarcoma (STS)
Victor Villalobos et al.
CANCER RESEARCH (2016)
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
Christopher W. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
William D. Tap et al.
LANCET (2016)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson et al.
LANCET ONCOLOGY (2014)
Targeting the PDGF signaling pathway in tumor treatment
Carl-Henrik Heldin
CELL COMMUNICATION AND SIGNALING (2013)
Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
David E. Gerber et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Rationale for the Development of IMC-3G3, a Fully Human Immunoglobulin G Subclass 1 Monoclonal Antibody Targeting the Platelet-Derived Growth Factor Receptor α
Gaurav D. Shah et al.
CANCER (2010)
Targeting the α Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis
Mike R. Russell et al.
CLINICAL CANCER RESEARCH (2010)
Platelet-derived growth factor receptor-α:: a novel therapeutic target in human hepatocellular cancer
Peggy Stock et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Autocrine activation of PDGFRα promotes the progression of ovarian cancer
D Matei et al.
ONCOGENE (2006)
Share Paper
